

Because of an error included within the Final Office Action that designated an incorrect phone number, and an incorrect name, of the Examiner in charge of examining this application, Applicant's several phone messages to the patent office were unanswered. As of this date, Applicants representative was informed that the case has been reassigned to Examiner Changhwa Cheu. The present paper is submitted as an informal proposed amendment. It is submitted that the amendment proposed herein places the claims in condition for allowance.

Because the presently submitted amendment places the case in condition for allowance, applicant submits that a formal request for extension of time is not needed. However, should such a request for extension be required, applicant's representative requests that this paper be considered to constitute the appropriate request for extension of time. Applicant hereby authorizes the payment of any fees to be deducted from Applicant's deposit account, 50-0364.

No new matter has been added by virtue of the present amendment.

### AMENDMENT

Please amend the claims as follows:

1. (Amended) A reagent for an assay to determine a hemostatic potential of a blood or plasma sample, said reagent comprising a coagulation activator wherein said activator is present at a concentration level [within a range sufficient] to trigger a thrombin formation but [insufficient] not to result in a complete fibrin polymerization of said blood or plasma sample,

wherein said reagent [may be] is utilized to assess a hypocoagulable, normal [or] and hypercoagulable condition in a single assay.

9. (Twice Amended) The reagent of claim 8, wherein the phospholipids comprise a phospholipid mixture comprising [all of] phosphatidylcholine, phosphotidylethanolamine, and phosphatidylserine and at a ratio of approximately from



1 to 10 [mole] percent phosphatidylserine and from about 5 to 30 [mole] percent phosphatidylethanolamine and the remainder phosphatidylcholine.

12. (Amended) The reagent of claim 4, wherein the metal cation is selected from the group consisting of magnesium, calcium [or] and manganese.

16. (Amended) The reagent of claim 15, wherein the protein C activator is purified human thrombomodulin, purified non-human mammalian thrombomodulin, soluble thrombomodulin [or] membrane associated thrombomodulin, native thrombomodulin [or] thrombomodulin reconstituted with phospholipids, partially [or fully] glycosylated thrombomodulin, fully glycosylated thrombomodulin, or fully deglycosylated thrombomodulin.

27. (Twice Amended) A reagent comprising:

a coagulation activator at a concentration of 11 picomoles or less, wherein said reagent [may be] is utilized to assess a hypocoagulable, normal [or] and hypercoagulable condition in a single assay.

28. (Amended) The reagent of claim 27, further comprising vesicles or liposomes.

37. (Twice Amended) The reagent of claim 30, wherein the metal cation is a divalent metal cation selected from the group consisting of manganese, calcium [or] and manganese.

83. (Amended) The reagent of claim 16, [wherein the thrombomodulin comprises] further comprising heparin.

88. (Twice amended) The reagent of claim 1, wherein [said fibrin polymerization is preceded by an initiation phase, and wherein] the coagulation activator detects defects in an [the] initiation phase.